A Case of Metastatic Collecting Duct Carcinoma Whose Massive Skull Bone Metastasis was Prominently Reossified by Gemcitabine Plus Cisplatin Chemotherapy Combined with Zoledronic Acid

Kikuchi, Makoto; Ito, Keiichi; Shimazaki, Hideyuki; Asano, Tomohiko

doi:10.1016/j.eucr.2017.07.002

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mPFS was 15.1 months and mOS was 27.8 months. We also previously reported on a patient with metastatic CDC whose massive skull bone metastases clearly reossified, lung metastases reduced and pleural effusion reduced by gemcitabine plus CDDP combined with zoledronic acid . Case reports reported on patients with metastatic CDC whose tumors responded by a TT, but the duration for disease control is generally short in metastatic CDC.…”

Section: Cdc Of Bellinimentioning

confidence: 98%

Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas

Ito

2019

Int J of Urology

Self Cite

View full text Add to dashboard Cite

Abbreviations & Acronyms AA = anti-angiogenic ALK = anaplastic lymphoma kinase ARE = anti-oxidant responsive element ccRCC = clear cell renal cell carcinoma CDC = collecting duct carcinoma ChRCC = chromophobe renal cell carcinoma CR = complete response CTLA-4 = cytotoxic Tlymphocyte antigen 4 EV = everolimus FH = fumarate hydratase IMDC = International Metastatic Renal Cell Carcinoma Database Consortium INF-a = interferon-a IO drug = immuno-oncology drug ISUP = International Society of Urological Pathology LOH = loss of heterozygosity MET+ = MET mutation+ METÀ = MET mutationÀ MiT = microphthalmiaassociated transcription mOS = median overall survival mPFS = median progressionfree survival mPRCC = metastatic papillary renal cell carcinoma mRCC = metastatic renal cell carcinoma MSKCC = Memorial Sloan-Kettering Cancer Center mTORi = mammalian target of rapamycin inhibitor MTSCC = mutinous tubular and spindle cell carcinoma NA = not availableAbstract: There is still no standard treatment for non-clear cell renal cell carcinomas. Sunitinib is the most examined drug because of its effectiveness in retrospective studies and clinical trials, and is the preferred first-line drug in the National Comprehensive Cancer Network guideline. Temsirolimus is an option as a first-line drug, especially for poor-risk non-clear cell renal cell carcinoma patients. Everolimus, pazopanib, axitinib and nivolmab might also be viable options. Clinical trials are still required to gather evidence regarding non-clear cell renal cell carcinoma treatment. Because each non-clear cell renal cell carcinoma has a different genetic background and molecular features, specific treatment for each non-clear cell renal cell carcinoma should be established. From the results of a Japanese multicenter study, tyrosine kinase inhibitors might be better used for metastatic papillary renal cell carcinoma in both first-and second-line settings. Both tyrosine kinase inhibitors and mammalian target of rapamicin inhibitors are effective for metastatic chromophobe renal cell carcinoma, but the preferred first-line drug has not been determined. Platinum-based chemotherapies are currently recommended for metastatic collecting duct carcinoma, and anti-angiogenic drugs are effective in some cases. Tyrosine kinase inhibitors, especially sunitinib, appear to be effective for X11.2 translocation renal cell carcinoma among the microphthalmia-associated transcription family of translocation renal cell carcinomas. Evidence is still lacking regarding the treatment for other rare non-clear cell renal cell carcinomas. Appropriate sequential therapies using antivascular endothelial growth factor therapies, mammalian target of rapamicin inhibitors and immuno-oncology drugs should be established for each nonclear cell renal cell carcinoma. None declared. References 1 Ito K. Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinoma. Int. J. Urol. 2019; 26: 868-77. 2 Teishima J, Inoue S, Hayashi T, Matsubara A. Current status of prognostic factors in ...

show abstract

Section: Cdc Of Bellinimentioning

confidence: 98%

Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas

Ito

2019

Int J of Urology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Current treatment options for CDC are based on standards set for renal cell carcinoma, but due to their aggressiveness and also with metastasis, the intervention such as cytoreductive nephrectomy is less useful for the survival of this case and more suitable for the management of RCC cells (ccRCC), which is known resistant to systemic chemotherapy (Sui et al, 2017). Majority of CDC with metastases have a very poor prognosis, but pathological similarities with UC are the main reason to use sophisticated chemotherapy agents such as Gemcitabine plus Cisplatin; therefore CDC may be chemosensitive/radiosensitive (Sui et al, 2017;Kawaguchi, Ito, Shimazaki, & Asano, 2017).…”

Section: Qanun Medika Volmentioning

confidence: 99%

Collecting Duct Carcinoma: A Rare Entity

Djawa¹,

Rahaju²

2020

Qanun Medika

View full text Add to dashboard Cite

Collecting duct carcinoma is a rare and highly aggressive subtype of renal cell carcinoma. The incidence rate is less than 1-2% of all renal tumors and usually, affect middle-aged adult, commonly in men. We reported a 76-year-old man complains of an intermittent painless gross hematuria, abdominal mass and left flank pain for approximately three months. The CT abdomen showed a slightly enhancing solid mass in the left kidney and para-aorta lymphadenopathy. Cut surfaces of the kidney showed a solid-cystic and ill-defined greyish-white tumor. Microscopically, tumor formed solid sheets and tubulopapillary structures lined by neoplastic cells, hobnailing nuclei, abnormal mitotic, and a desmoplastic stroma with lymphoplasmacytic infiltration, and the immunochemical profile were PAX8 (+) /p63 (-). Based on these findings, the diagnosis was a collecting duct carcinoma. This tumor arising from the collecting duct of Bellini in the renal medulla, accounts for less than 1-2% of all renal masses and important to be distinguished from other tumors due to differences in prognosis and therapeutic. Histopathological examination is needed to establish the diagnosis. A case of collecting duct carcinoma that occurred in a 76-year-old man has been reported. A definitive diagnosis can only be done with a detailed histopathological examination for patient management benefits.Keywords : renal cell carcinoma, collecting duct carcinoma, urothelial carcinoma, PAX8, p63

show abstract

Cisplatin/gemcitabine/zoledronic acid

2017

Reactions Weekly

View full text Add to dashboard Cite

A Case of Metastatic Collecting Duct Carcinoma Whose Massive Skull Bone Metastasis was Prominently Reossified by Gemcitabine Plus Cisplatin Chemotherapy Combined with Zoledronic Acid

Cited by 3 publications

References 4 publications

Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas

Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas

Collecting Duct Carcinoma: A Rare Entity

Cisplatin/gemcitabine/zoledronic acid

Contact Info

Product

Resources

About